Literature DB >> 14976315

Use of CD134 as a primary receptor by the feline immunodeficiency virus.

Masayuki Shimojima1, Takayuki Miyazawa, Yasuhiro Ikeda, Elizabeth L McMonagle, Hayley Haining, Hiroomi Akashi, Yasuhiro Takeuchi, Margaret J Hosie, Brian J Willett.   

Abstract

Feline immunodeficiency virus (FIV) induces a disease similar to acquired immunodeficiency syndrome (AIDS) in cats, yet in contrast to human immunodeficiency virus (HIV), CD4 is not the viral receptor. We identified a primary receptor for FIV as CD134 (OX40), a T cell activation antigen and costimulatory molecule. CD134 expression promotes viral binding and renders cells permissive for viral entry, productive infection, and syncytium formation. Infection is CXCR4-dependent, analogous to infection with X4 strains of HIV. Thus, despite the evolutionary divergence of the feline and human lentiviruses, both viruses use receptors that target the virus to a subset of cells that are pivotal to the acquired immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976315     DOI: 10.1126/science.1092124

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  98 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection.

Authors:  Isabelle Dietrich; Elizabeth L McMonagle; Sarah J Petit; Swetha Vijayakrishnan; Nicola Logan; Chi N Chan; Greg J Towers; Margaret J Hosie; Brian J Willett
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 3.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

4.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

5.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

6.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

7.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 8.  Human gene therapy vectors derived from feline lentiviruses.

Authors:  Román A Barraza; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

Review 9.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.